If you have been reading about pituitary axis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-31. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
== Chemistry == Cement materials can be classified into two distinct categories: hydraulic cements and non-hydraulic cements according to their respective setting and hardening mechanisms. Hydraulic cement setting and hardening involves hydration reactions and therefore requires water, while non-hydraulic cements only react with a gas and can directly set under air.
Mikania micrantha is a tropical plant in the family Asteraceae; known as bitter vine, climbing hemp vine, or American rope. It is also sometimes called mile-a-minute vine (a moniker also used for the unrelated Persicaria perfoliata). It is a vigorously growing perennial creeper that grows best in areas in high humidity, light and soil fertility, though it can adapt in less fertile soils. The featherlike seeds are dispersed by wind. A single stalk can produce between 20 and 40 thousand seeds a season. The species is native to the sub-tropical zones of North, Central, and South America.
=== Prediction and analysis of drug targets === RNApred: Prediction of RNA binding proteins from its amino acid sequence. ProPrint: Prediction of interaction between proteins from their amino acid sequence. DomPrint: A domain-domain interaction (DDI) prediction server. MycoPrint: A web interface for exploration of the interactome of Mycobacterium tuberculosis H37Rv (Mtb) predicted by the "Domain Interaction Mapping" (DIM) method. ATPint: A server for predicting ATP interacting residues in proteins. FADpred: Identification of FAD interacting residues in proteins. GTPbinder: Prediction of protein GTP interacting residues. NADbinder: Prediction of NAD binding residues in proteins. PreMier: Software for predicting mannose interacting residues in proteins. DMAP: Designing of mutants of antibacterial peptides. icaars: Prediction and classification of aminoacyl tRNA synthetases using PROSITE domains. CBtope: Prediction of conformational B-cell epitope in a sequence from its amino acid sequence. DesiRM: Designing of Complementary and Mismatch siRNAs for silencing a gene. GenomeABC: A server for benchmarking of genome assemblers.
=== Sulfhydryl biotinylation === An alternative to primary amine biotinylation is to label sulfhydryl groups with biotin. Because free sulfhydryl groups are less prevalent on most proteins compared to primary amines, sulfhydryl biotinylation is useful when primary amines are located in the regulatory domain(s) of the target protein or when a reduced level of biotinylation is required. Sulfhydryl-reactive groups such as maleimides, haloacetyls and pyridyl disulfides, require free sulfhydryl groups for conjugation; disulfide bonds must first be reduced to free up the sulfhydryl groups for biotinylation. If no free sulfhydryl groups are available, lysines can be modified with various thiolation reagents (Traut's reagent, SAT(PEG4), SATA and SATP), resulting in the addition of a free sulfhydryl. Sulfhydryl biotinylation is performed at a slightly lower pH (6.5-7.5) than labeling with NHS esters.
Sources: en.wikipedia.org
Here we assumed the local pressure gradient is not too great to have any compressibility effects. Though locally we ignored the effects of pressure variation due to density variation, over long distances these effects are taken into account. Since μ is independent of pressure, the above equation can be integrated over the length L to give
Because of this, and also because the high-glycerol method seems to protect the red blood cells better and is associated with less haemolysis than the low-glycerol method, the high-glycerol method is often preferred.
=== Environmental factors === Hyperglycemia is lower in higher income groups since there is access to better education, healthcare, and resources. Low-middle income groups are more likely to develop hyperglycemia, due in part to a limited access to education and a reduced availability of healthy food options. Living in warmer climates can reduce hyperglycemia due to increased physical activity while people are less active in colder climates.
Over 100 different genetic defects leading to Wilson's disease have been described and are available on the Internet at [1]. Some of the mutations have geographic clustering. Many Wilson's patients carry different mutations on each chromosome 13 (i.e., they are compound heterozygotes). Even in individuals who are homozygous for a mutation, onset and severity of the disease may vary. Individuals homozygous for severe mutations (e.g., those truncating the protein) have earlier disease onset. Disease severity may also be a function of environmental factors, including the amount of copper in the diet or variability in the function of other proteins that influence copper homeostasis. It has been suggested that heterozygote carriers of the Wilson's disease gene mutation may be potentially more susceptible to elevated copper intake than the general population. A heterozygotic frequency of 1/90 people has been estimated in the overall population. However, there is no evidence to support this speculation. Further, a review of the data on single-allelic autosomal recessive diseases in humans does not suggest that heterozygote carriers are likely to be adversely affected by their altered genetic status.
Little Caesars sold its first franchise in 1962 and, by 1987, had restaurants in all 50 states. Throughout the 1990s and early 2000s, Little Caesars were commonly found in Kmart stores, more specifically in Big Kmarts and Super Kmart. Little Caesars pizza was also included in many older, remodeled Kmart locations. The first Kmarts with Little Caesars were built in Garden City, Michigan. After Kmart's bankruptcy issues, many Kmarts replaced the Little Caesars restaurants with their own branded "K-Cafe". However, as of 2021, two Little Caesars/Kmart locations remain– in Guam and USVI. Between 2008 and 2015, Little Caesars was the fastest-growing pizza chain in the United States. As of 2017, the company had 5,463 locations including U.S. and international units. The estimated total investment necessary to begin the operation of a Little Caesars Franchise ranges from $378,700 to $1,695,500.
Sources: en.wikipedia.org
=== Ubiquitin-independent degradation === Although most substrates must be ubiquitinated before being degraded by the 26S proteasome, there are some exceptions to this general rule, especially when the proteasome plays a normal role in the post-translational processing of the protein. The proteasomal activation of NF-κB by processing p105 into p50 via internal proteolysis is one major example. Some proteins that are hypothesized to be unstable due to intrinsically unstructured regions, are degraded in a ubiquitin-independent manner. Ubiquitin-independent mechanisms targeting key cell cycle regulators such as p53 have also been reported, although p53 is also subject to ubiquitin-dependent degradation. Finally, structurally abnormal, misfolded, or highly oxidized proteins are also subject to ubiquitin-independent and 19S-independent degradation under conditions of cellular stress. The most well-known example of a ubiquitin-independent proteasome substrate is the enzyme ornithine decarboxylase (ODC). ODC is degraded upon the expression and binding to a cofactor, Ornithine decarboxylase antizyme (AZ) that breaks the ODC dimer. ODC contains either a C-terminal disordered region (in human) or an N-terminal disordered region (in yeast) is necessary for degradation and is proposed to engage the AAA motor of the 19S RP, however the mechanistic details of this interaction have yet to be identified. Another example of ubiquitin independent degradation is Thymidine synthetase, where an N-terminal disordered region is essential for degradation.
isoelectronicity The phenomenon of two or more chemical species (atoms, molecules, ions, etc.) being composed of different elements but having the same number of valence electrons and the same structural arrangement (i.e. the same number of atoms with the same connectivity). Isoelectronic species typically show useful consistency and predictability in their chemical properties.
The Supreme Court consists of nine justices, including the chief justice of the United States, and decides cases before it by majority vote. When the Senate conducts an impeachment trial of a sitting president, the chief justice presides. Like other Article III judges, Supreme Court justices are nominated by the president and confirmed by the Senate and hold office during good behavior.
The analytical technique on which the process of resonance ionization is based is termed resonance ionization mass spectrometry (RIMS). RIMS is derived from the original method, resonance ionization spectroscopy (RIS), which was initially being used to detect single atoms with better time resolution. RIMS has proved useful in the investigation of radioactive isotopes (such as for studying rare fleeting isotopes produced in high-energy collisions), trace analysis (such as for discovering impurities in highly pure materials), atomic spectroscopy (such as for detecting low-content materials in biological samples), and for applications in which high levels of sensitivity and elemental selectivity are desired.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.